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patterns, and rates of comorbid conditions that exist in pa-
tients treated on each regimen. These estimates can be used
to calculate and project cost of therapy for patients suffer-
ing from HIV/AIDS.
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OBJECTIVES: The object of the present assay was to ana-
lyze the type and amount of expenses for the family with a
child suffering from bronchial asthma living in Vladivostok
between 1996–1998.
METHODS: 500 families with asthmatic children were
surveyed retrospectively and anonymously.
RESULTS: Direct expenditures for the child’s disease
were 10,98  0,94% of annual income. Pharmacotherapy
was the main expense item (75,96  1,2%). Drug expenses
for one child were US$302, 86  10, 4 in 1996, US$356,
72  19, 8 in 1997. In 1998 the dollar amount of pharma-
cotherapy didn’t change greatly (US$344, 4  20, 2) but a
slump in exchange value of the ruble without an adequate
increase of ruble income led to expenses growing as a per-
centage of family income (22, 1  2, 1%). Self-control
means expenditures appeared in 1997 and by the end of
1998 19  2,25% of families had sustained them. Doctor
visits and sanatorium and health resort expenses per child
were 7–8% of direct expenditures for asthma. Less than
5% of families have the means to buy an air cleaning appa-
ratus and hypoallergic linen. The unit price is US$100–
2100 but annual income of a family with an asthmatic
child in Vladivostok in 1997 was US$3493  50, 4, in
1998  US$2996  94, 5. Owing to the child’s disease one
of the parents in a third of families either had to be totally
unemployed or take low qualified work that aggravated fi-
nancial loss. Annually 12,2  2,1 disablement days fall on
the family because of asthma.
CONCLUSIONS: In order to evaluate a family’s real
means to follow medical recommendations it’s necessary to
take into consideration family expenses for asthma. Eco-
nomic state aggravation in the country in August 1998 led
to abrupt reduction or interruption of basic asthma therapy
in 37, 86  4, 36% families for financial reasons. 82, 8 
1, 67% of parents find the disease to be a considerable fi-
nancial burden for the family.
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OBJECTIVES: To investigate the cost-effectiveness of us-
ing an increased dose of disodium cromoglycate versus
switching to budesonide treatment in those children with
moderate asthma whose symptoms can not be controlled
with the recommended dose of cromoglycate.
METHODS: An open, randomized, parallel group design
clinical trial was conducted at 20 study centres. After a
4-week run-in period, 131 children with uncontrolled
symptoms were randomized either to the treatment of
increased disodium cromoglycate 4  40 mg daily or
budesonide 2  200 g daily for a 12-week treatment
period. An intention-to-treat analysis was performed. Ef-
ficacy variables were the morning PEF value and the
number of symptom free days. The economic analysis
was based on a societal perspective. Protocol driven
costs were excluded from the analysis. Direct costs were
measured as costs of study medication, rescue medica-
tion, non-protocol driven visits, and number of days
stayed at hospital. Indirect cost measurement was based
on time missing from school. A sensitivity analysis was
carried out on resource use data to test final cost-effec-
tiveness.
RESULTS: The morning PEF value increased more from
baseline in the budesonide group (30.8 vs. 10.6; p 
0.01). The average number of symptom free days was
higher in the budesonide group (65.7 vs. 59.5; p  0.09).
The average cost of therapy was lower in the budesonide
group (HUF 7844 vs. HUF 16962; p  0.0001). The cost
per symptom free day was HUF 119 in the budesonide
group and HUF 285 in the cromoglycate group.
CONCLUSIONS: Budesonide treatment was the domi-
nant strategy as it lead to both superior clinical outcomes
and cost savings.
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